



HAL
open science

Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor for survival in the community.

Laure Carcaillon, Karine Pérès, Jean-Jacques Péré, Catherine Helmer,
Jean-Marc Orgogozo, Jean-François Dartigues

► **To cite this version:**

Laure Carcaillon, Karine Pérès, Jean-Jacques Péré, Catherine Helmer, Jean-Marc Orgogozo, et al.. Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor for survival in the community.. Dementia and Geriatric Cognitive Disorders, 2007, 23 (6), pp.439-45. 10.1159/000102017 . inserm-00173047

HAL Id: inserm-00173047

<https://inserm.hal.science/inserm-00173047>

Submitted on 10 Nov 2009

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Title: Fast cognitive decline at the time of dementia diagnosis: a major prognostic factor**
2 **for survival in the community.**

3 **Authors:** Laure Carcaillon¹, Karine Pérès¹, Jean-Jacques Péré², Catherine Helmer¹, Jean-Marc
4 Orgogozo¹⁻³, Jean-François Dartigues¹⁻³

5

6 ¹ Inserm Unit 593, University Victor Segalen Bordeaux 2, France

7 ² Novartis, France

8 ³ University Hospital Center, University Victor Segalen Bordeaux 2, France

9

10

11

12 Corresponding author :

13

14 **Jean-François DARTIGUES**

15 Inserm U593 - PAQUID - Case 11

16 146 rue Léo Saignat

17 33076 Bordeaux Cedex, France

18 Email: jean-francois.dartigues@isped.u-bordeaux2.fr

19 Tel.: + 33 5 57 57 15 02

20 Fax: + 33 5 57 57 14 86

21

1 **Abstract**

2 *Background/Aims:* Current findings suggest the existence of a category of fast cognitive
3 decliners with poorer prognosis but better treatment response. Our study aimed at confirming the
4 concept of fast decliner at the time of Alzheimer’s disease (AD) diagnosis which best predicts
5 mortality, in an unselected sample.

6 *Methods:* 245 incident cases of AD were selected from the French longitudinal cohort PAQUID.
7 We investigated different threshold of cognitive decline (measured by the annual loss of points
8 in MMSE score) to define when a subject could be considered as a fast decliner. We used Cox
9 proportional hazard models to study the relation between cognitive decline and mortality.

10 *Results:* The significant threshold of decline associated with higher mortality rate was a loss of 3
11 points per year in MMSE score. Among the 245 AD cases, 83 (33.9%) subjects were considered
12 as fast decliners. Of them, 78.3% died during the follow-up compared with 63.0% of the slow
13 decliners (RR=1.7, 95% CI [1.2 – 2.5]).

14 *Conclusion:* These results constituted an empirical validation of the concept of fast decliners in
15 community based AD patients and justified the cut-off of 3 points for the definition of this
16 condition.

17

18 Key words: Rapid progression, mortality, Alzheimer’s disease

19

1 **Introduction**

2 A progressive cognitive decline is the main characteristic of Alzheimer's disease (AD).
3 However, this decline widely varies among subjects at the onset of the disease and the distinction
4 between slow and fast decliners has been recently emphasized [1]. In addition, the association
5 between severe cognitive decline during the course of AD and a higher mortality has already
6 been described [2-5].

7 On the whole, current findings suggest that fast decliners need a particular clinical attention as
8 they have poorer prognosis with higher mortality rates [6]. Yet, the notion of fast decliners
9 remains arbitrary and needs more validation. Indeed, such a category of patients was identified
10 during post-hoc analyses, in selected clinical samples participating to clinical trials [7]. These
11 samples were constituted with patients previously chosen because they presented specific
12 characteristics and thus were not representative of the population. In addition, the previous
13 studies on the relationship between cognitive decline and mortality have analyzed the decline
14 over the whole course of the disease but not specifically at the phase following the diagnosis [2,
15 8, 9] while this period of time seems the more relevant phase to provide adequate early
16 information and to better manage the patient and his family.

17 Thus, the practical interest of the concept of fast decliner needs to be confirmed for its prognostic
18 value at the time of AD diagnosis, in an unselected sample. Longitudinal population-based
19 studies with long term follow-ups are necessary to conduct such a validation. The French
20 longitudinal PAQUID study [10] allowed us to analyze unselected new cases of AD occurring in
21 the general population. Moreover, this cohort provides data on the evolution of cognitive
22 performances over the 13 years of follow-up and thus the cognitive decline at the time of
23 dementia diagnosis, as well as a long term follow-up of the patients until death.

24 The aim of this study was to define a category of fast cognitive decliners at the time of AD
25 diagnosis which best predicts mortality, in a sample of AD cases in the general population. We
26 investigated different thresholds of decline to define when a subject could be considered as a fast

1 decliner. To do so, we selected 245 subjects prospectively screened for AD from the PAQUID
2 cohort and we focused on the relation between the annual rate of cognitive decline at the time of
3 AD diagnosis and the risk of mortality.

4

1 **Methods**

2 *Study design*

3 Our data came from the PAQUID (Personnes Agées QUID) cohort, study on cerebral and
4 functional aging. The detailed methodology of the PAQUID study has been described in full
5 elsewhere [10]. The baseline visit began in 1988-1989.

6 Overall, 3777 subjects accepted to participate and signed a written consent. At baseline the
7 participants were visited at home by a neuropsychologist and re-interviewed similarly 1 (in
8 Gironde only), 3, 5, 8, 10 and 13 years after the baseline assessment.

9 An active research of dementia with confirmation by a senior neurologist was conducted at each
10 follow-up as detailed below.

11 *Sample selection*

12 In the present study, after exclusion of the 102 subjects demented at baseline, our sample
13 included all the cases of possible or probable AD diagnosed between the 1-year-visit and the 10-
14 year-visit (n=328). We did not include the demented subjects diagnosed after the 10-year-visit.

15 Let us refer to the visit of diagnosis of AD as “ADV”. In order to study the cognitive decline,
16 subjects had to be seen at the visit preceding ADV (“ADV-1”) and had to have performed the
17 global cognitive evaluation test: Mini Mental Status Examination (MMSE) at both these visits.

18 Finally, our sample included 245 subjects, after exclusion of 83 subjects with missing value for
19 MMSE either at ADV or at ADV-1. There was no statistical difference on age, sex or education
20 between these 83 subjects and the rest of the sample.

21 *Data collection and dementia diagnosis*

22 Interviews were performed at home by a trained psychologist with a standardized questionnaire,
23 which contained socio demographic characteristics, objective and subjective physical health, and
24 a set of neuropsychological tests. This battery of tests included an evaluation of the global
25 mental status (with the MMSE) [11], visual memory (Benton’s Visual Retention Test) [12],
26 visuo-spatial attention (Zazzo’s cancellation test) [13], verbal fluency (Isaac Set Test) [14], and

1 simple logical reasoning and attention (Wechsler's Digit Symbol Test) [15]. At the end of the
2 neuropsychological interview, the psychologist filled in the Diagnostic and Statistical Manual of
3 Mental Disorders 3rd ed., revised (DSM-III-R) to select subjects suspected of being demented
4 [16]. Those suspected cases were seen by a senior neurologist, blinded to the psychometric
5 battery and functional assessment, to confirm or rule out the diagnosis of dementia. The
6 specialist also precise the etiology of dementia with the NINCDS-ADRDA criteria for
7 Alzheimer's disease [17] and the Hachinski score for vascular dementia [18]. Cases were
8 classified as probable or possible Alzheimer disease, vascular dementia, and other types of
9 dementia.

10 For all the incident cases of dementia, the same procedure of diagnosis was used at each follow-
11 up, but in order to increase the screening sensitivity, the criterion of a cognitive loss of three
12 points in MMSE score from the previous visit was added to qualify for neurological
13 examination.

14 Finally, the survival status was collected throughout the follow-up for each participant up to the
15 13-year-visit.

16 *Rate of cognitive decline: calculation*

17 The annual rate of cognitive decline at the time of AD diagnosis was based on the MMSE
18 evolution between ADV-1 and ADV. This score ranges from 0 to 30, and higher scores indicate
19 better cognitive functioning. The annual rate of decline was calculated by subtracting the MMSE
20 score obtained at ADV-1 from the score reached at ADV (in order to have a positive indicator, as
21 the last measure is mostly lower than the previous one). Finally, the annual rate of cognitive
22 decline was obtained by dividing this difference by the delay (in years) between the two visits.

23 *Data analysis*

24 After describing the sample, we studied the association between rate of cognitive decline and
25 mortality. Survival time was considered from ADV to death for deceased subjects or to the 13-

1 year-visit for not deceased subjects. We tested five different thresholds of decline: a loss of at
2 least one, two, three, four and five points per year in the MMSE between ADV and the ADV-1.
3 Risk of mortality was assessed using Cox proportional hazards models [19]. For each of the five
4 thresholds of cognitive decline investigated, we represented, on the same figure, estimated
5 univariate survival curves and the curve corresponding to the loss of less than 1 point a year.
6 Then, we controlled our models for potential confounding factors: age at ADV, sex, level of
7 education (subjects were considered as highly educated if they had obtained the French primary
8 school certificate, corresponding to about seven years of schooling, which was previously
9 validated as the best cut-off for the prediction of dementia in the PAQUID study) [20], and
10 MMSE score at ADV in two categories (less or more than 19). We previously examined whether
11 age and MMSE scores should be modeled as continuous or categorical variables and we
12 concluded that age should be used as a continuous variable and MMSE scores as a categorical
13 variable with a cut off of 19. Validity of the proportional hazard assumption was evaluated by
14 testing interaction time dependant variables and by a graphical evaluation.

15 Afterwards, we investigated if the category of fast decliners associated with a higher risk of
16 mortality had other characteristics that could explain their faster decline. To do so, we compared
17 slow and fast decliners on sex, age at inclusion and at ADV, education, level of MMSE at ADV
18 and ADV-1, social situation at ADV (family situation, type of residence, and number of close
19 family or friends), bed restriction at ADV, blindness and deafness at ADV, etiology of the
20 disease (probable or possible AD), symptomatic depression at ADV and ADV-1, medications at
21 ADV and ADV-1 (antidepressant and anticholinergic).

22

1 **Results**

2 *Sample description*

3 Our sample was constituted with 245 subjects with AD. Table 1 presents the main socio
4 demographic and health characteristics of our sample. The mean age was 78.8 years old at
5 inclusion and it was 85.5 years old at ADV. Seventy percents of the sample were women, 26.9%
6 of the subjects were living alone, and 81.9% had more than 3 close family or friends. Possible
7 AD cases represented more than 52.0% of total AD diagnosed. In all, 18.7% suffered from
8 symptomatic depression at ADV and 13.9% at the ADV-1.

9 *Variable of interest*

10 The mean MMSE score was 17.5 at ADV and 23.2 at ADV-1 (table 1). The mean delay between
11 these two visits was 2.2 years (SD=0.6) and ranged from 0.9 to 4.0 years. The annual loss of
12 points in MMSE between ADV and ADV-1 was 2.2 (SD=2.3) in average and ranged from -3.3
13 (a gain of 3.3 points per year) to 16.1 points (Fig. 1).

14 Regarding the different thresholds of decline, 205 subjects (83.7%) lost one point or more per
15 year in MMSE, 133 subjects (54.3%) lost two points or more, 83 (33.9%) lost three points or
16 more, 44 (18.0%) lost four points or more, and 21 (8.6%) lost five points or more.

17 *Thresholds of cognitive decline and risk of mortality*

18 Between ADV and the 13-year-visit, 167 (68.2 %) subjects died. According to the thresholds of
19 1, 2, 3, 4 and 5 points loss, respectively 139 (67.8%), 95 (71.4%), 65 (78.3%), 37 (84.1%), and
20 17 (81.0%) subjects died in the category of fast decliners.

21 Table 2 presents both univariate and multivariate results of the Cox proportional hazard models
22 for each of the three thresholds. The univariate Relative Risks (RR) of death among subjects who
23 lost at least more than 2, 3, 4 and 5 points were significantly increased. The risk of death was not
24 significantly different between slow and fast decliners with the threshold of 1 point. Fig. 2 shows
25 the estimated survival curves following ADV for the five thresholds of loss and for the loss of

1 less than 1 point per year in MMSE. The survival time is different (shorter) for the decline of 3, 4
2 and 5 points or more.

3 Controlled for age, sex, level of education, and MMSE score at ADV, the risk of death remained
4 non significant for the threshold of 1 point ($p = 0.593$) and no longer reached the significance for
5 the threshold of 2 points ($p = 0.193$). For the thresholds of 3, 4 and 5 points, the risk of death
6 remained significantly increased after adjustments (respectively, $RR=1.7$, 95% CI: 1.2-2.5,
7 $RR=2.1$, 95% CI: 1.4-3.2, $RR=2.1$, 95% CI: 1.2-3.6). As expected, the risk of death increased
8 with age and was higher among men, whereas there was no association with MMSE score at
9 ADV, irrespective of the threshold.

10 *Characteristics of fast decliners*

11 We choose to define the category of fast decliners according to the 3 points threshold as it was
12 the first threshold to significantly increase the risk of mortality. Table 3 presents socio
13 demographic and health characteristics of slow and fast decliners defined on the threshold of 3
14 points. Neither sex nor education was associated with the category of decline. However, fast
15 decliners were older at ADV and at inclusion. Fast decliners had significantly lower MMSE
16 scores at ADV (13.2 versus 19.7) although they had similar scores at ADV-1 (23.5 versus 23.0).
17 In addition, fast decliners were more likely to be in a nursing home (44.6% versus 14.8%). No
18 significant difference was observed between slow and fast decliners in terms of family situation
19 and number of close family or friends. Six subjects were bed restricted at ADV and they were all
20 fast decliners. Yet, neither blindness nor deafness was related to the category of decline. More
21 fast decliners were diagnosed as possible AD than slow decliners (61.5% versus 47.5%).
22 Symptomatic depression at ADV and at ADV-1 was not associated with the category of decline.
23 However, it is to be noted that 26.9% of the fast decliners suffered from symptomatic depression
24 at ADV, compared with 15.4% of the slow decliners. Fast decliners had been more often
25 hospitalized during the year before the diagnosis than slow decliners (54.4% versus 31.7%).
26 Concerning medications, whereas slow and fast decliners were as much under antidepressant at

1 ADV, fast decliners were significantly less treated by antidepressant at ADV-1 (3.9% versus
2 14.2%). On the contrary, compared with slow decliners, fast decliners were significantly more
3 treated with anticholinergic at ADV (28.9% versus 17.4%) although there was no difference at
4 ADV-1.
5

1 **Discussion**

2 In this population-based prospective study, we found that in AD patients, fast cognitive decline
3 at the time of the disease was a strong prognostic factor for survival. The significant threshold of
4 decline was 3 points loss or more per year in the MMSE score, while the thresholds of 2 or 1
5 points per year were not significantly associated with survival after appropriate adjustments.
6 According to the threshold of 3 points, we searched if specific characteristics could explain this
7 faster decline. None of the socio demographic characteristics appeared to be different according
8 to this threshold. Fast decliners were more likely to have been hospitalized during the year
9 before ADV than slow decliners and were more often living into nursing home. In addition, fast
10 decliners were more often under anticholinergic drugs than slow decliners. This last result is
11 consistent with the association, previously found in the PAQUID study, between anticholinergic
12 drugs and low cognitive performances [21]. Moreover, as cholinergic drugs are assumed to avoid
13 fast decline, this association between fast decline and anticholinergic drugs deserves further
14 investigations. These findings constituted an empirical validation of the concept of fast decliner
15 in community-based AD patients and justified the cut-off of 3 points for the definition of this
16 condition.

17 The strength of this study is that it was conducted on an unselected sample of AD patients and
18 that the decline of MMSE was effectively measured before the diagnosis of dementia and not
19 only estimated as proposed by Doody et al [22]. Some authors have already pointed out this 3-
20 points per year threshold [7], but their data were not validated by a follow-up study.

21 The loss of 3 points or more in MMSE at the time of AD diagnosis may traduce an aggravation
22 of the disease. One assumption is the faster progression of the underlying pathological process of
23 AD. Indeed, the rate at which senile plaques and neurofibrillary tangles accumulate in the brain
24 may increase and thus lead to a diminution of cognitive functions. Another assumption is the
25 failure of compensatory mechanisms. It is well known that cognitive reserves decrease the

1 deleterious effect of senile plaques on cognitive abilities [23, 24]. Thus, the collapse of these
2 reserves could explain the decrease of cognitive functions.

3 Our study presents some limitations. It is known that before 1995, in many countries, subjects
4 with Lewy Body disease were often classify as possible AD. In the PAQUID study, demented
5 subjects with Parkinsonism were excluded from the possible AD group. Therefore, only a
6 minority of subjects with Lewy Body disease may be included in the class of possible AD group.
7 Hence, our results should not be affected by the presence of these subjects.

8 Moreover, we tested five different thresholds of decline; therefore we are under the possibility of
9 accepting a false positive association because of multiple testing. However, using the correction
10 advised by Bonferroni, the p-value associated with the 3-points threshold remains significant as
11 it has to be compared with 0.01.

12 In the PAQUID study, subjects were visited every 2 or 3 years and thus, there is an imprecision
13 on the actual date of diagnosis. When a subject is diagnosed, it can actually be demented for
14 more than 2 years as well as for only a few months. Thus, one could be considered as a fast
15 decliner and another could be considered as a slow decliner. This bias may lead to overestimate
16 the relation between cognitive decline and mortality. However, our analyses were adjusted for
17 cognitive level at ADV which prevent our results from such overestimation.

18 To conclude, the loss of 3 points per year in MMSE identifies a group of fast decliners with a
19 higher risk of mortality. This category of patients seems to have consistently a more aggressive
20 disease and thus needs a particular attention at follow-up. In addition, their treatments must be
21 adapted. As the great majority of our subjects were not treated by cholinesterase inhibitors, this
22 finding enhances the interest of knowing that fast decliners better respond to this type of
23 medication [6]. Indeed, reducing the speed of cognitive decline may prevent the subjects from a
24 precipitated death. Clinical trials should be conducted in order to determine whether or not the
25 risk of death can be reduced among this category of fast decliners.

Table 1: Socio demographic and health characteristics of the subjects

	n	%
Female (versus male)	171	69.8
Primary education level (versus no diploma)	122	49.8
Family situation at ADV ¹ (alone versus not alone)	66	26.9
Number of close family or friends at ADV (3 or more versus less than 3)	95	81.9
Etiology (possible AD versus probable AD)	128	52.2
Symptomatic depression at ADV	34	18.7
Symptomatic depression at ADV-1 ²	32	13.9
	m	SD
Age at baseline	78.84	6.0
Age at ADV	85.48	6.0
MMSE at ADV	17.48	5.5
MMSE at ADV-1	23.21	3.7

Values are number (n), % or mean (m), standard deviation (SD)

¹ ADV = Visit of Alzheimer's disease diagnosis

² ADV-1 = Visit before ADV

Table 2: Univariate and multivariate risks of death for the three thresholds of cognitive decline

	Univariate			Multivariate		
	RR	95% CI	p-value	RR	95% CI	p-value
Model 1						
Annual loss of points in MMSE ≥ 1	1.19	(0.79-1.79)	0.399	0.89	(0.58-1.37)	0.593
Sex (male versus female)				1.58	(1.11-2.26)	0.012
Age at ADV ¹				1.08	(1.05-1.12)	<.001
At least primary education				1.23	(0.90-1.69)	0.186
MMSE at ADV ≥ 19				0.73	(0.53-1.02)	0.063
Model 2						
Annual loss of points in MMSE ≥ 2	1.36	(1.00-1.85)	0.048	1.24	(0.90-1.71)	0.193
Sex (male versus female)				1.59	(1.11-2.27)	0.011
Age at ADV				1.09	(1.05-1.12)	<.001
At least primary education				1.17	(0.86-1.60)	0.326
MMSE at ADV ≥ 19				0.79	(0.57-1.10)	0.161
Model 3						
Annual loss of points in MMSE ≥ 3	1.78	(1.30-2.43)	<.001	1.71	(1.18-2.47)	0.005
Sex (male versus female)				1.62	(1.13-2.32)	0.009
Age at ADV				1.09	(1.06-1.12)	<.001
At least primary education				1.06	(0.77-1.47)	0.714
MMSE at ADV ≥ 19				0.95	(0.66-1.37)	0.779
Model 4						
Annual loss of points in MMSE ≥ 4	2.33	(1.61-3.37)	<.001	2.11	(1.39-3.20)	<.001
Sex (male versus female)				1.57	(1.10-2.24)	0.014
Age at ADV				1.08	(1.05-1.12)	<.001
At least primary education				1.16	(0.85-1.58)	0.363
MMSE at ADV ≥ 19				0.93	(0.65-1.33)	0.692
Model 5						
Annual loss of points in MMSE ≥ 5	3.11	(1.95-5.21)	<.001	2.19	(1.20-3.61)	0.009
Sex (male versus female)				1.53	(1.07-2.19)	0.019
Age at ADV				1.08	(1.05-1.11)	<.001
At least primary education				1.21	(0.89-1.65)	0.226
MMSE at ADV ≥ 19				0.82	(0.59-1.15)	0.258

Values are relative risks (RR), 95% confidence interval (CI)

¹ ADV = Visit of Alzheimer's disease diagnosis

Table 3: Characteristics of subjects according to the threshold of 3 points

	Threshold 3		p-value
	<3 n = 162	>=3 n = 83	
	n (%)	n (%)	
Female (versus male)	111 (68.5)	60 (72.3)	0.543
Primary education level (versus no diploma)	75 (46.3)	47 (56.6)	0.126
Family situation at ADV ¹ (alone versus not alone)	48 (29.6)	18 (21.7)	0.185
Type of residence at ADV:			<0.001
Home or old people housing	135 (83.3)	41 (49.4)	
Nursing home	24 (14.8)	37 (44.6)	
Other	3 (1.9)	5 (6.0)	
Number of close family or friends at ADV (3 or more versus less than 3)	66 (84.6)	29 (76.3)	0.276
Bed restricted at ADV	0	6 (7.4)	0.001
Total blindness at ADV	3 (1.9)	2 (2.5)	0.733
Deafness at ADV	17 (10.6)	10 (12.8)	0.605
Etiology (possible AD versus probable AD)	77 (47.5)	51 (61.5)	0.039
Symptomatic depression at ADV	20 (15.4)	14 (26.9)	0.071
Symptomatic depression at ADV-1	20 (13.2)	12 (15.4)	0.644
Hospitalized during the year before ADV	51 (31.7)	43 (54.4)	0.001
Antidepressant at ADV	31 (20.0)	15 (19.7)	0.963
Antidepressant at ADV-1	22 (14.2)	3 (3.9)	0.019
Anticholinergic at ADV	27 (17.4)	22 (28.9)	0.044
Anticholinergic at ADV-1	28 (18.1)	17 (22.4)	0.438
	m (SD)	m (SD)	
Age at inclusion	78.0 (5.9)	80.5 (6.0)	0.002
Age at ADV	84.8 (5.8)	86.8 (6.1)	0.013
MMSE at ADV	19.7 (3.5)	13.2 (6.2)	<0.001
MMSE at ADV-1	23.0 (3.8)	23.5 (3.5)	0.323

Values are number (%) or mean (SD)

¹ ADV = Visit of Alzheimer's disease diagnosis

² ADV-1 = Visit before ADV

Acknowledgements

The PAQUID project was funded by: ARMA (Bordeaux); Caisse Nationale d'Assurance Maladie des Travailleurs Salariés (CNAMTS); Conseil Général de la Dordogne; Conseil Général de la Gironde; Conseil Régional d'Aquitaine; Fondation de France; France Alzheimer (Paris); GIS Longévité; Institut National de la Santé et de la Recherche Médicale (INSERM); Mutuelle Générale de l'Education Nationale (MGEN); Mutualité Sociale Agricole (MSA); NOVARTIS Pharma (France); SCOR Insurance (France).

References

- 1 Farlow M R, Hake A, Messina J, Hartman R, Veach J and Anand R: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. *Arch Neurol* 2001; 58: 417-22.
- 2 Schupf N, Tang M X, Albert S M, Costa R, Andrews H, Lee J H and Mayeux R: Decline in cognitive and functional skills increases mortality risk in nondemented elderly. *Neurology* 2005; 65: 1218-26.
- 3 Schupf N, Costa R, Tang M X, Andrews H, Tycko B, Lee J H and Mayeux R: Preservation of cognitive and functional ability as markers of longevity. *Neurobiol Aging* 2004; 25: 1231-40.
- 4 Bassuk S S, Wypij D and Berkman L F: Cognitive impairment and mortality in the community-dwelling elderly. *Am J Epidemiol* 2000; 151: 676-88.
- 5 Bruce M L, Hoff R A, Jacobs S C and Leaf P J: The effects of cognitive impairment on 9-year mortality in a community sample. *J Gerontol B Psychol Sci Soc Sci* 1995; 50: P289-96.
- 6 Farlow M R, Small G W, Quarg P and Krause A: Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. *Dement Geriatr Cogn Disord* 2005; 20: 192-7.
- 7 O'Hara R, Thompson J M, Kraemer H C, Fenn C, Taylor J L, Ross L, Yesavage J A, Bailey A M and Tinklenberg J R: Which Alzheimer patients are at risk for rapid cognitive decline? *J Geriatr Psychiatry Neurol* 2002; 15: 233-8.
- 8 Wilson R S, Li Y, Aggarwal N T, McCann J J, Gilley D W, Bienias J L, Barnes L L and Evans D A: Cognitive decline and survival in Alzheimer's disease. *Int J Geriatr Psychiatry* 2006; 21: 356-62.
- 9 Larson E B, Shadlen M F, Wang L, McCormick W C, Bowen J D, Teri L and Kukull W A: Survival after initial diagnosis of Alzheimer disease. *Ann Intern Med* 2004; 140: 501-9.
- 10 Dartigues J F, Gagnon M, Michel P, Letenneur L, Commenges D, Barberger-Gateau P, Auriacombe S, Rigal B, Bedry R, Alperovitch A and et al.: [The Paquid research program on the epidemiology of dementia. Methods and initial results]. *Rev Neurol (Paris)* 1991; 147: 225-30.
- 11 Folstein M F, Folstein S E and McHugh P R: "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* 1975; 12: 189-98.
- 12 Benton A: Manuel pour l'application du test de rétention visuelle. Applications cliniques et expérimentales. 2ème édition française. Paris : Centre de Psychologie Appliquée 1965.
- 13 Zazzo R: Test des deux barrages. Actualités pédagogiques et psychologiques, Vol. 7. Neuchâtel: Delachaux et Niestle, 1974.
- 14 Isaacs B and Kennie A T: The Set test as an aid to the detection of dementia in old people. *Br J Psychiatry* 1973; 123: 467-70.
- 15 Wechsler D: WAIS-R Manual. New York : Psychological Corporation' 1981.
- 16 Pichot P: [DSM-III: the 3d edition of the Diagnostic and Statistical Manual of Mental Disorders from the American Psychiatric Association]. *Rev Neurol (Paris)* 1986; 142: 489-99.
- 17 McKhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan E M: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* 1984; 34: 939-44.
- 18 Hachinski V C, Iliff L D, Zilhka E, Du Boulay G H, McAllister V L, Marshall J, Russell R W and Symon L: Cerebral blood flow in dementia. *Arch Neurol* 1975; 32: 632-7.
- 19 Cox D: Regression models in life tables (with discussion). *Journal of the royal statistical society. Serie B.* 1972; 34: 187-220.
- 20 Letenneur L, Gilleron V, Commenges D, Helmer C, Orgogozo J M and Dartigues J F: Are sex and educational level independent predictors of dementia and Alzheimer's disease? Incidence data from the PAQUID project. *J Neurol Neurosurg Psychiatry* 1999; 66: 177-83.

- 21 Lechevallier-Michel N, Molimard M, Dartigues J F, Fabrigoule C and Fourrier-Reglat A: Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study. *Br J Clin Pharmacol* 2005; 59: 143-51.
- 22 Doody R S, Massman P and Dunn J K: A method for estimating progression rates in Alzheimer disease. *Arch Neurol* 2001; 58: 449-54.
- 23 Stern Y, Tang M X, Denaro J and Mayeux R: Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment. *Ann Neurol* 1995; 37: 590-5.
- 24 Stern Y, Gurland B, Tatemichi T K, Tang M X, Wilder D and Mayeux R: Influence of education and occupation on the incidence of Alzheimer's disease. *Jama* 1994; 271: 1004-10.

Legends to figures

Figure 1. Annual loss of points in the MMSE prior to AD diagnosis

Figure 2. Kaplan-Meier survival curves after the diagnosis of AD stratified by the rate of cognitive decline